BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 37370681)

  • 1. Pan-cancer analysis of telomere maintenance mechanisms.
    Hakobyan M; Binder H; Arakelyan A
    J Biol Chem; 2024 May; 300(6):107392. PubMed ID: 38763334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic Regulation of Telomere Maintenance for Therapeutic Interventions in Gliomas.
    Naderlinger E; Holzmann K
    Genes (Basel); 2017 May; 8(5):. PubMed ID: 28513547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomere Maintenance Mechanisms in Cancer.
    Gaspar TB; Sá A; Lopes JM; Sobrinho-Simões M; Soares P; Vinagre J
    Genes (Basel); 2018 May; 9(5):. PubMed ID: 29751586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutically targeting the unique disease landscape of pediatric high-grade gliomas.
    Fernando D; Ahmed AU; Williams BRG
    Front Oncol; 2024; 14():1347694. PubMed ID: 38525424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining old and new concepts in targeting telomerase for cancer therapy: transient, immediate, complete and combinatory attack (TICCA).
    Ali JH; Walter M
    Cancer Cell Int; 2023 Sep; 23(1):197. PubMed ID: 37679807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Glia Telomere Dysfunction in the Pathogenesis of Central Nervous System Diseases.
    Papageorgakopoulou MA; Bania A; Lagogianni IA; Birmpas K; Assimakopoulou M
    Mol Neurobiol; 2024 Jan; ():. PubMed ID: 38240992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT).
    De Vitis M; Berardinelli F; Sgura A
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of telomere maintenance and associated therapeutic vulnerabilities in malignant gliomas.
    Waitkus MS; Erman EN; Reitman ZJ; Ashley DM
    Neuro Oncol; 2024 Jun; 26(6):1012-1024. PubMed ID: 38285162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative Lengthening of Telomeres in Pediatric High-Grade Glioma and Therapeutic Implications.
    Umaru B; Sengupta S; Senthil Kumar S; Drissi R
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative lengthening of telomeres (ALT) in pediatric high-grade gliomas can occur without ATRX mutation and is enriched in patients with pathogenic germline mismatch repair (MMR) variants.
    Stundon JL; Ijaz H; Gaonkar KS; Kaufman RS; Jin R; Karras A; Vaksman Z; Kim J; Corbett RJ; Lueder MR; Miller DP; Guo Y; Santi M; Li M; Lopez G; Storm PB; Resnick AC; Waanders AJ; MacFarland SP; Stewart DR; Diskin SJ; Rokita JL; Cole KA
    Neuro Oncol; 2023 Jul; 25(7):1331-1342. PubMed ID: 36541551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Elimination of Osteosarcoma Cell Lines with Short Telomeres by Ataxia Telangiectasia and Rad3-Related Inhibitors.
    Goncalves T; Zoumpoulidou G; Alvarez-Mendoza C; Mancusi C; Collopy LC; Strauss SJ; Mittnacht S; Tomita K
    ACS Pharmacol Transl Sci; 2020 Dec; 3(6):1253-1264. PubMed ID: 33344901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas.
    Dorris K; Sobo M; Onar-Thomas A; Panditharatna E; Stevenson CB; Gardner SL; Dewire MD; Pierson CR; Olshefski R; Rempel SA; Goldman S; Miles L; Fouladi M; Drissi R
    J Neurooncol; 2014 Mar; 117(1):67-76. PubMed ID: 24477622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer Cells with Alternative Lengthening of Telomeres Do Not Display a General Hypersensitivity to ATR Inhibition.
    Deeg KI; Chung I; Bauer C; Rippe K
    Front Oncol; 2016; 6():186. PubMed ID: 27602331
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.